Skip to main content
SpringerLink
Log in

CCN6 (WISP3): a new anti-cancer therapy?

  • Bits and Bytes
  • Published:
Journal of Cell Communication and Signaling Aims and scope

Abstract

The CCN family of matricellular proteins are dysregulated in cancers, and may strategies targeting them may represent novel approaches to treating these diseases. A recent study from Huang and colleagues (Cancer Res. 70: 3340-50, 2010) suggests that CCN6 (WISP3) is downregulated in aggressive breast cancers, and this phenomenon may result in the promotion of tumor survival. CCN6 may represent a novel therapeutic approach to breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Brigstock DR (2003) The CCN family: a new stimulus package. J Endocrinol 178:169–175

    Google Scholar 

  • Chen CC, Lau LF (2009) Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 41:771–783

    Article  CAS  PubMed  Google Scholar 

  • Chu CY, Chang CC, Prakash E, Kuo ML (2008) Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci 15:675–685

    Article  CAS  PubMed  Google Scholar 

  • Holbourn KP, Acharya KR, Perbal B (2008) The CCN family of proteins: structure-function relationships. Trends Biochem Sci 33:461–473

    Article  CAS  PubMed  Google Scholar 

  • Huang W, Zhang Y, Varambally S et al (2008) Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol 172:893–904

    Article  CAS  PubMed  Google Scholar 

  • Huang W, Gonzalez ME, Toy KA, Banerjee M, Kleer CG (2010) Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells. Cancer Res 70:3340–3350

    Article  CAS  PubMed  Google Scholar 

  • Leask A (2009a) Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2. J Cell Commun Signal 3:161–162

    Article  PubMed  Google Scholar 

  • Leask A (2009b) Death of a tumor: targeting CCN in pancreatic cancer. J Cell Commun Signal 3:159–160

    Article  PubMed  Google Scholar 

  • Leask A (2010) Yin and Yang Part Deux: CCN5 inhibits the pro-fibrotic effects of CCN2. J Cell Commun Signal 4:155–156

    Article  PubMed  Google Scholar 

  • Leask A, Abraham DJ (2006) All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 119:4803–4810

    Article  CAS  PubMed  Google Scholar 

  • Leu SJ, Lam SC, Lau LF (2002) Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical vein endothelial cells. J Biol Chem 277:46248–46255

    Article  CAS  PubMed  Google Scholar 

  • O'Kelly J, Chung A, Lemp N, Chumakova K, Yin D, Wang HJ, Said J, Gui D, Miller CW, Karlan BY, Koeffler HP (2008) Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol 33:59–67

    PubMed  Google Scholar 

  • Perbal B (2001) NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 54:57–79

    Article  CAS  PubMed  Google Scholar 

  • Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, Eguchi T, Sasaki A, Takigawa M (2006) Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21:1045–1059.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Dentistry and Physiology and Pharmacology, University of Western Ontario, Dental Sciences Building, London, ON, N6A 5C1, Canada

    Andrew Leask

Authors
  1. Andrew Leask
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Leask.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leask, A. CCN6 (WISP3): a new anti-cancer therapy?. J. Cell Commun. Signal. 4, 199–200 (2010). https://doi.org/10.1007/s12079-010-0106-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12079-010-0106-y

Keywords

Search

Navigation